

Emmanuel Roilides

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2491674/publications.pdf>

Version: 2024-02-01

274
papers

13,425
citations

36303

51
h-index

27406

106
g-index

289
all docs

289
docs citations

289
times ranked

12185
citing authors

#	ARTICLE	IF	CITATIONS
1	Late-onset neonatal sepsis: genetic differences by sex and involvement of the NOTCH pathway. <i>Pediatric Research</i> , 2023, 93, 1085-1095.	2.3	8
2	Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial. <i>The Lancet Child and Adolescent Health</i> , 2022, 6, 49-59.	5.6	7
3	Evaluating posaconazole, its pharmacology, efficacy and safety for the prophylaxis and treatment of fungal infections. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 175-199.	1.8	6
4	Emergence of ST39 carbapenem-resistant <i>Klebsiella pneumoniae</i> producing VIM-1 and KPC-2. <i>Microbial Pathogenesis</i> , 2022, 162, 105373.	2.9	6
5	Neonatal Sepsis and Hemostasis. <i>Diagnostics</i> , 2022, 12, 261.	2.6	7
6	Multicenter Prospective Study of Biomarkers for Diagnosis of Invasive Candidiasis in Children and Adolescents. <i>Clinical Infectious Diseases</i> , 2022, 75, 248-259.	5.8	10
7	Invasive Trichosporonosis in Neonates and Pediatric Patients with Malignancies or Hematologic Disorders. <i>Pathogens</i> , 2022, 11, 242.	2.8	2
8	Changes in molecular epidemiology of carbapenem-resistant <i>Klebsiella pneumoniae</i> in the intensive care units of a Greek hospital, 2018–2021. <i>Acta Microbiologica Et Immunologica Hungarica</i> , 2022, , .	0.8	3
9	A Longitudinal Study of Spontaneous Gut Decolonization of Carbapenem-resistant Gram-negative Bacteria in Neonatal and Pediatric Patients. <i>Pediatric Infectious Disease Journal</i> , 2022, 41, 648-653.	2.0	1
10	A national study of antibiotic use in Greek pediatric hematology oncology and bone marrow transplant units. <i>Antimicrobial Stewardship & Healthcare Epidemiology</i> , 2022, 2, .	0.5	2
11	Epidemiology and outcomes of ventilator-associated events in critically ill children: Evaluation of three different definitions. <i>Infection Control and Hospital Epidemiology</i> , 2022, , 1-6.	1.8	6
12	Paediatric cutaneous mucormycosis: A case report and review of the literature. <i>Mycoses</i> , 2022, 65, 674-682.	4.0	5
13	Adherence to Recommendations for <i>Î</i> acillus Calmette-GuÃ©rin Vaccination of High-risk Neonates in Greece. <i>Pediatric Infectious Disease Journal</i> , 2022, 41, 857-859.	2.0	1
14	Targeted Genotyping of MIS-C Patients Reveals a Potential Alternative Pathway Mediated Complement Dysregulation during COVID-19 Infection. <i>Current Issues in Molecular Biology</i> , 2022, 44, 2811-2824.	2.4	4
15	Transmission dynamics of SARSâ€CoVâ€2 within families with children in Greece: A study of 23 clusters. <i>Journal of Medical Virology</i> , 2021, 93, 1414-1420.	5.0	65
16	Activities of nine antifungal agents against <i>Candida auris</i> biofilms. <i>Mycoses</i> , 2021, 64, 381-384.	4.0	9
17	Perioperative antimicrobial prophylaxis in adult patients: The first multicenter clinical practice audit with intervention in Greek surgical departments. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 702-709.	1.8	5
18	Efficacy of <i>Î</i> â€lactam/ <i>Î</i> â€lactamase inhibitors to treat extendedâ€spectrum betaâ€lactamaseâ€producing <i>Enterobacterales</i> bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENTâ€SOT Project). <i>Transplant Infectious Disease</i> , 2021, 23, e13520.	1.7	10

#	ARTICLE	IF	CITATIONS
19	Microbiology and infectivity. , 2021, , 331-338.		0
20	Harmonising regulatory approval for antibiotics in children. The Lancet Child and Adolescent Health, 2021, 5, 96-98.	5.6	6
21	A global point prevalence survey of antimicrobial use in neonatal intensive care units: The no-more-antibiotics and resistance (NO-MAS-R) study. EClinicalMedicine, 2021, 32, 100727.	7.1	33
22	The Impact of Carbapenem Resistance on Mortality in Patients With Klebsiella Pneumoniae Bloodstream Infection: An Individual Patient Data Meta-Analysis of 1952 Patients. Infectious Diseases and Therapy, 2021, 10, 541-558.	4.0	18
23	The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis. Mycoses, 2021, 64, 798-808.	4.0	149
24	Reducing Duration of Antibiotic Use for Presumed Neonatal Early-Onset Sepsis in Greek NICUs. A "Low-Hanging Fruit" Approach. Antibiotics, 2021, 10, 275.	3.7	5
25	Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies. Journal of Fungi (Basel, Switzerland), 2021, 7, 186.	3.5	18
26	The Synergistic Effects of a Complementary Physiotherapeutic Scheme in the Psychological and Nutritional Treatment in a Teenage Girl with Type 1 Diabetes Mellitus, Anxiety Disorder and Anorexia Nervosa. Children, 2021, 8, 443.	1.5	1
27	Population Pharmacokinetics and Outcomes of Critically Ill Pediatric Patients Treated with Intravenous Colistin at Higher Than Recommended Doses. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	7
28	8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncology, The, 2021, 22, e254-e269.	10.7	89
29	Aetiology of acute respiratory infection in preschool children requiring hospitalisation in Europe—results from the PED-MERMAIDS multicentre case-control study. BMJ Open Respiratory Research, 2021, 8, e000887.	3.0	10
30	Ertapenem for treatment of non-severe bacteremic urinary-tract infections due to ESBL-producing Enterobacterales in kidney transplant recipients: a propensity score and DOOR-based analysis.. Antimicrobial Agents and Chemotherapy, 2021, 65, e0110221.	3.2	2
31	COVID-19 infodemics: the role of mainstream and social media. Clinical Microbiology and Infection, 2021, 27, 1568-1569.	6.0	9
32	Activity of Amphotericin B Formulations and Voriconazole, Alone or in Combination, against Biofilms of <i>Scenedosporium</i> and <i>Fusarium</i> spp.. Antimicrobial Agents and Chemotherapy, 2021, 65, e0063821.	3.2	3
33	SARS-CoV-2 molecular testing in Greek hospital paediatric departments: a nationwide study. Epidemiology and Infection, 2021, 149, e70.	2.1	3
34	MixInYeast: A Multicenter Study on Mixed Yeast Infections. Journal of Fungi (Basel, Switzerland), 2021, 7, 13.	3.5	14
35	Potential benefit from the implementation of the Kaiser Permanente neonatal early-onset sepsis calculator on clinical management of neonates with presumed sepsis. European Journal of Pediatrics, 2021, 181, 1001.	2.7	2
36	Invasive Mucormycosis in Children With Malignancies: Report From the Infection Working Group of the Hellenic Society of Pediatric Hematology-Oncology. Journal of Pediatric Hematology/Oncology, 2021, 43, 176-179.	0.6	6

#	ARTICLE	IF	CITATIONS
37	630. Emergence of Colistin Resistance in the OVERCOME Trial: Impact of Combination Therapy with Meropenem. <i>Open Forum Infectious Diseases</i> , 2021, 8, S418-S419.	0.9	1
38	1143. Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonatal and Pediatric Participants With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized, Clinical Trial. <i>Open Forum Infectious Diseases</i> , 2021, 8, S663-S664.	0.9	0
39	1159. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Pediatric Participants With Confirmed or Suspected Gram-negative Bacterial Infections: A Phase 1b, Open-label, Single-Dose Clinical Trial. <i>Open Forum Infectious Diseases</i> , 2021, 8, S671-S671.	0.9	3
40	638. The Impact of <i>in vitro</i> Synergy Between Colistin and Meropenem on Clinical Outcomes in Invasive Carbapenem-resistant Gram-negative Infections: A Report from the OVERCOME Trial. <i>Open Forum Infectious Diseases</i> , 2021, 8, S421-S422.	0.9	1
41	Forecasting models of infections due to carbapenem-resistant Gram-negative bacteria in an intensive care unit in an endemic area. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 20, 214-218.	2.2	1
42	Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network. <i>Archives of Disease in Childhood</i> , 2020, 105, 26-31.	1.9	56
43	Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia. <i>American Journal of Transplantation</i> , 2020, 20, 1629-1641.	4.7	17
44	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020, 71, 1367-1376.	5.8	1,429
45	Etiology and Outcome of Candidemia in Neonates and Children in Europe. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 114-120.	2.0	57
46	Immunomodulatory effects of colistin on host responses against carbapenem-resistant <i>Klebsiella pneumoniae</i> biofilms. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106182.	2.5	6
47	Pulmonary Infectious Complications in Children with Hematologic Malignancies and Chemotherapy-Induced Neutropenia. <i>Diseases (Basel, Switzerland)</i> , 2020, 8, 32.	2.5	7
48	Population Pharmacokinetics of Teicoplanin in Preterm and Term Neonates: Is It Time for a New Dosing Regimen?. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	8
49	Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients. <i>Journal of Clinical Oncology</i> , 2020, 38, 3205-3216.	1.6	63
50	Management of osteoarticular fungal infections in the setting of immunodeficiency. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 461-474.	4.4	10
51	Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 305-309.	2.0	19
52	Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial. <i>PLoS ONE</i> , 2020, 15, e0229380.	2.5	34
53	Pharmacokinetics and Pharmacodynamics of Antifungal Agents in Neonates and Children. <i>Current Fungal Infection Reports</i> , 2020, 14, 317-328.	2.6	0
54	An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 329.	1.6	6

#	ARTICLE	IF	CITATIONS
55	Epstein-Barr Encephalitis in a Child with Congenital Human Immunodeficiency Virus Infection: A Case Report Calling for No Forgetfulness. <i>Current HIV Research</i> , 2020, 18, 63-66.	0.5	1
56	Effects of an Active Surveillance Program and Enhanced Infection Control Measures on Carbapenem-Resistant Gram-Negative Bacterial Carriage and Infections in Pediatric Intensive Care. <i>Microbial Drug Resistance</i> , 2019, 25, 1347-1356.	2.0	8
57	Immunomodulatory Properties of Antifungal Agents on Immune Functions of the Host. , 2019, , 941-951.		0
58	Risk factors for carbapenem resistance and outcomes when treating bloodstream infections in a paediatric intensive care unit. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2019, 108, 1923-1924.	1.5	1
59	ECMM <i>Candi</i> Regâ€”A ready to use platform for outbreaks and epidemiological studies. <i>Mycoses</i> , 2019, 62, 920-927.	4.0	19
60	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e405-e421.	9.1	970
61	Invasive Candidiasis in Infants and Children: Recent Advances in Epidemiology, Diagnosis, and Treatment. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019, 5, 11.	3.5	30
62	Successful treatment of rhinoorbital mucormycosis due to <i>Rhizopus arrhizus</i> with liposomal amphotericin B, posaconazole and surgical debridement in a child with neuroblastoma. <i>Medical Mycology Case Reports</i> , 2019, 25, 10-14.	1.3	2
63	Adaptive Immunotherapy for Opportunistic Infections. , 2019, , 1019-1030.		0
64	Polyclonal predominance of concurrently producing OXA-23 and OXA-58 carbapenem-resistant <i>Acinetobacter baumannii</i> strains in a pediatric intensive care unit. <i>Molecular Biology Reports</i> , 2019, 46, 3497-3500.	2.3	8
65	Acquired resistance in fungi: how large is the problem?. <i>Clinical Microbiology and Infection</i> , 2019, 25, 790-791.	6.0	4
66	A Prospective, Open-label Study to Assess the Safety, Tolerability and Efficacy of Anidulafungin in the Treatment of Invasive Candidiasis in Children 2 to <18 Years of Age. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 275-279.	2.0	22
67	Invasive Aspergillosis in Pediatric Leukemia Patients: Prevention and Treatment. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019, 5, 14.	3.5	9
68	Standardising neonatal and paediatric antibiotic clinical trial design and conduct: the PENTA-ID network view. <i>BMJ Open</i> , 2019, 9, e032592.	1.9	4
69	Use of Ceftazidime-avibactam for the Treatment of Extensively drug-resistant or Pan drug-resistant <i>Klebsiella pneumoniae</i> in Neonates and Children <5 Years of Age. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 812-815.	2.0	33
70	Disseminated mucormycosis in an adolescent kidney transplant recipient. <i>Kidney International</i> , 2019, 95, 236.	5.2	1
71	Molecular Epidemiology of Endemic Carbapenem-Resistant Gram-Negative Bacteria in an Intensive Care Unit. <i>Microbial Drug Resistance</i> , 2019, 25, 712-716.	2.0	18
72	Dose-Dependent Synergistic Interactions of Colistin with Rifampin, Meropenem, and Tigecycline against Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	19

#	ARTICLE	IF	CITATIONS
73	Prevalence, geographic risk factor, and development of a standardized protocol for fungal isolation in cystic fibrosis: Results from the international prospective study "MFIP" Journal of Cystic Fibrosis, 2019, 18, 212-220.	0.7	38
74	Efficacy and Safety of Echinocandins for the Treatment of Invasive Candidiasis in Children. Pediatric Infectious Disease Journal, 2019, 38, 42-49.	2.0	14
75	Comparison of semiquantitative and differential time to positivity methods for the diagnosis of central line-associated bloodstream infections in an intensive care unit. Access Microbiology, 2019, 1, e000029.	0.5	1
76	Fatal rhinocerebral mucormycosis in a patient with ulcerative colitis receiving azathioprine and corticosteroid. Current Medical Mycology, 2019, 5, 37-41.	0.8	6
77	Thiamine Deficiency in a Child with Short Bowel Syndrome and Review. Pediatric Gastroenterology, Hepatology and Nutrition, 2019, 22, 493.	1.2	6
78	Candidemia due to <i>Candida guilliermondii</i> in an immuno-compromised infant: a case report and review of literature. Current Medical Mycology, 2019, 5, 32-36.	0.8	10
79	Pharmacokinetics of Daptomycin in Critically Ill Pediatric Patients. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	5
80	Molecular epidemiology of carbapenem-resistant <i>Pseudomonas aeruginosa</i> in an endemic area: comparison with global data. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1211-1220.	2.9	44
81	Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey. The Lancet Global Health, 2018, 6, e619-e629.	6.3	392
82	Voriconazole Antifungal Prophylaxis in Children With Malignancies: A Nationwide Study. Journal of Pediatric Hematology/Oncology, 2018, 40, 22-26.	0.6	15
83	2302. Bloodstream Infections Due to Carbapenem-Resistant Gram-Negative Bacteria in Pediatric Intensive Care Unit (PICU): Risk Factors and Outcomes. Open Forum Infectious Diseases, 2018, 5, S683-S683.	0.9	0
84	Ventilator-associated pneumonia in neonates and children: a systematic analysis of diagnostic methods and prevention. Future Microbiology, 2018, 13, 1431-1446.	2.0	41
85	Advances in the Treatment of Mycoses in Pediatric Patients. Journal of Fungi (Basel, Switzerland), 2018, 4, 115.	3.5	11
86	Surveillance for central-line-associated bloodstream infections: Accuracy of different sampling strategies. Infection Control and Hospital Epidemiology, 2018, 39, 1210-1215.	1.8	2
87	Impact of active surveillance and infection control measures on carbapenem-resistant Gram-negative bacterial colonization and infections in intensive care. Journal of Hospital Infection, 2018, 99, 396-404.	2.9	42
88	Intravenous fosfomycin in patients with liver disease for extensively drug-resistant Gram-negative bacteria. Journal of Infection, 2018, 77, 448-454.	3.3	5
89	Azole-Resistance in <i>Aspergillus terreus</i> and Related Species: An Emerging Problem or a Rare Phenomenon?. Frontiers in Microbiology, 2018, 9, 516.	3.5	66
90	Recent Advances in the Treatment of Scedosporiosis and Fusariosis. Journal of Fungi (Basel, Switzerland), 2018, 4, 115.	3.5	49

#	ARTICLE	IF	CITATIONS
91	Identification of <i>Mucorales</i> in patients with proven invasive mucormycosis by polymerase chain reaction in tissue samples. <i>Mycoses</i> , 2018, 61, 909-915.	4.0	34
92	Pharmacodynamic and Immunomodulatory Effects of Micafungin on Host Responses against Biofilms of <i>Candida parapsilosis</i> in Comparison to Those of <i>Candida albicans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	10
93	Bone and joint infections caused by mucormycetes: A challenging osteoarticular mycosis of the twenty-first century. <i>Medical Mycology</i> , 2017, 55, myw136.	0.7	27
94	Antimicrobial dosing in neonates. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1-4.	3.1	5
95	Epidemiological surveillance of multidrug-resistant gram-negative bacteria in a solid organ transplantation department. <i>Transplant Infectious Disease</i> , 2017, 19, e12686.	1.7	33
96	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 726-734.	9.1	367
97	Molecular epidemiology of carbapenem-resistant <i>Acinetobacter baumannii</i> in Greece: an extended review (2000-2015). <i>Future Microbiology</i> , 2017, 12, 801-815.	2.0	34
98	OUP accepted manuscript. <i>Medical Mycology</i> , 2017, 55, 859-868.	0.7	19
99	Epidemiology of Invasive Fungal Disease in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2017, 6, S3-S11.	1.3	144
100	Diagnostic Imaging and Invasive Fungal Diseases in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2017, 6, S22-S31.	1.3	52
101	Current and potential treatment options for invasive <i>Candida</i> infections. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 799-812.	0.8	0
102	Immune responses to <i>Mucorales</i> growth forms: Do we know everything?. <i>Virulence</i> , 2017, 8, 1489-1491.	4.4	6
103	Performance of QuantiFERON®-TB Gold In-Tube assay in children receiving disease modifying anti-rheumatic drugs. <i>World Journal of Pediatrics</i> , 2017, 13, 472-478.	1.8	7
104	Point-prevalence survey of healthcare facility-onset healthcare-associated <i>Clostridium difficile</i> infection in Greek hospitals outside the intensive care unit: The C. DEFINE study. <i>PLoS ONE</i> , 2017, 12, e0182799.	2.5	8
105	Cluster-distinguishing genotypic and phenotypic diversity of carbapenem-resistant Gram-negative bacteria in solid-organ transplantation patients: a comparative study. <i>Journal of Medical Microbiology</i> , 2017, 66, 1158-1169.	1.8	6
106	A Rare Case of Disseminated Pyogenic Gonococcal Infection in an Immunocompetent Woman. <i>Case Reports in Infectious Diseases</i> , 2016, 2016, 1-4.	0.5	4
107	A Rare Case of Clavicle Osteomyelitis in a Child and Literature Review. <i>Case Reports in Pediatrics</i> , 2016, 2016, 1-5.	0.4	7
108	Micafungin alters the amino acid, nucleic acid and central carbon metabolism of <i>Candida albicans</i> at subinhibitory concentrations: novel insights into mechanisms of action. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 72, dkw478.	3.0	8

#	ARTICLE	IF	CITATIONS
109	Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries. <i>BMC Infectious Diseases</i> , 2016, 16, 667.	2.9	109
110	Evaluation of the New Centers for Disease Control and Prevention Ventilator-Associated Event Module and Criteria in Critically Ill Children in Greece. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 1162-1166.	1.8	19
111	Molecular epidemiology of carbapenem-resistant <i>Klebsiella pneumoniae</i> in Greece. <i>Future Microbiology</i> , 2016, 11, 809-823.	2.0	50
112	Aspergillus arthritis: analysis of clinical manifestations, diagnosis, and treatment of 31 reported cases. <i>Medical Mycology</i> , 2016, 55, myw077.	0.7	25
113	Successful therapy of <i>Candida pulcherrima</i> fungemia in a premature newborn with liposomal amphotericin B and micafungin. <i>Medical Mycology Case Reports</i> , 2016, 12, 24-27.	1.3	4
114	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1362-1371.	3.0	89
115	Diagnosis of invasive fungal diseases in pediatric patients. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 1203-1213.	4.4	13
116	Nosocomial bloodstream infections in neurosurgery: a 10-year analysis in a center with high antimicrobial drug-resistance prevalence. <i>Acta Neurochirurgica</i> , 2016, 158, 1647-1654.	1.7	19
117	Differential effects of antifungal agents on expression of genes related to formation of <i>Candida albicans</i> biofilms. <i>Mycoses</i> , 2016, 59, 43-47.	4.0	2
118	Comparison of cotrimoxazole vs. second-generation cephalosporins for prevention of urinary tract infections in children. <i>Pediatric Nephrology</i> , 2016, 31, 2271-2276.	1.7	4
119	Can repurposing of existing drugs provide more effective therapies for invasive fungal infections?. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1179-1182.	1.8	14
120	<i>Candida</i> Arthritis: Analysis of 112 Pediatric and Adult Cases. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofv207.	0.9	31
121	Effects of fluconazole on the metabolomic profile of <i>Candida albicans</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 635-640.	3.0	19
122	Isavuconazole: an azole active against mucormycosis. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 761-762.	9.1	10
123	Biofilms and Antifungal Susceptibility Testing. <i>Methods in Molecular Biology</i> , 2016, 1356, 183-197.	0.9	3
124	Long-term outcome of parapneumonic effusions in children: Lung function and exercise tolerance. <i>Pediatric Pulmonology</i> , 2015, 50, 615-620.	2.0	10
125	Fungal Endocarditis in Neonates. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 803-808.	2.0	10
126	Osteoarticular Infections Caused by Non-Aspergillus Filamentous Fungi in Adult and Pediatric Patients. <i>Medicine (United States)</i> , 2015, 94, e2078.	1.0	36

#	ARTICLE	IF	CITATIONS
127	How Biofilms Evade Host Defenses. <i>Microbiology Spectrum</i> , 2015, 3, .	3.0	121
128	Mucormycosis (Zygomycosis). , 2015, , 159-168.		0
129	Role of Echinocandins in Fungal Biofilm-Related Disease: Vascular Catheter-Related Infections, Immunomodulation, and Mucosal Surfaces. <i>Clinical Infectious Diseases</i> , 2015, 61, S622-S629.	5.8	28
130	The Role of Echinocandins in Candida Biofilm-Related Vascular Catheter Infections: In Vitro and In Vivo Model Systems. <i>Clinical Infectious Diseases</i> , 2015, 61, S618-S621.	5.8	39
131	Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients: an update. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 693-710.	1.8	13
132	Successful treatment of <i>Candida</i> osteoarticular infections with limited duration of antifungal therapy and orthopedic surgical intervention. <i>Infectious Diseases</i> , 2015, 47, 144-149.	2.8	14
133	Diagnosing ventilator-associated pneumonia in pediatric intensive care. <i>American Journal of Infection Control</i> , 2015, 43, 390-393.	2.3	13
134	Antipseudomonal Agents Exhibit Differential Pharmacodynamic Interactions with Human Polymorphonuclear Leukocytes against Established Biofilms of <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2198-2205.	3.2	7
135	Invasive Fungal Infections in Pediatric Solid Organ Transplant Patients: Epidemiology and Management. <i>Current Fungal Infection Reports</i> , 2015, 9, 57-64.	2.6	1
136	Methylprednisolone impairs conidial phagocytosis but does not attenuate hyphal damage by neutrophils against <i>Exserohilum rostratum</i> . <i>Medical Mycology</i> , 2015, 53, 189-193.	0.7	6
137	In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against <i>Candida albicans</i> biofilms. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 470-478.	3.0	96
138	Successful management of an outbreak due to carbapenem-resistant <i>Acinetobacter baumannii</i> in a neonatal intensive care unit. <i>European Journal of Pediatrics</i> , 2015, 174, 65-74.	2.7	31
139	BCG vaccination policy in Greece: time for another review?. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 1258-1258.	1.2	2
140	Mannose binding lectin and ficolin-2 polymorphisms are associated with increased risk for bacterial infections in children with B acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1017-1022.	1.5	15
141	Reply to "Detection of Multiple Fungal Species in Blood Samples by Real-Time PCR: an Interpretative Challenge". <i>Journal of Clinical Microbiology</i> , 2014, 52, 3517-3517.	3.9	0
142	Micafungin in Premature and Non-premature Infants. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, e291-e298.	2.0	31
143	Reply to "Not Over Yet: Fungal Infections following Methyl Prednisolone Injections Smoulder On". <i>Journal of Clinical Microbiology</i> , 2014, 52, 3508-3508.	3.9	0
144	Rare Fungal Infections in Children: An Updated Review of the Literature. <i>Current Fungal Infection Reports</i> , 2014, 8, 21-36.	2.6	4

#	ARTICLE	IF	CITATIONS
145	Current management of late onset neonatal bacterial sepsis in five European countries. <i>European Journal of Pediatrics</i> , 2014, 173, 997-1004.	2.7	34
146	Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 52-59.	2.5	188
147	<i>Aspergillus osteomyelitis</i> : Epidemiology, clinical manifestations, management, and outcome. <i>Journal of Infection</i> , 2014, 68, 478-493.	3.3	93
148	<i>Exserohilum</i> infections: Review of 48 cases before the 2012 United States outbreak. <i>Medical Mycology</i> , 2014, 52, 376-386.	0.7	43
149	Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. <i>Lancet Oncology</i> , The, 2014, 15, e327-e340.	10.7	325
150	<i>In Vitro</i> Combination of Isavuconazole with Micafungin or Amphotericin B Deoxycholate against Medically Important Molds. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6934-6937.	3.2	39
151	Pathogenesis and host defence against Mucorales: the role of cytokines and interaction with antifungal drugs. <i>Mycoses</i> , 2014, 57, 40-47.	4.0	26
152	Efficacy and safety of linezolid for the treatment of infections in children: a meta-analysis. <i>European Journal of Pediatrics</i> , 2014, 173, 1179-1186.	2.7	7
153	Caspofungin at Catheter Lock Concentrations Eradicates Mature Biofilms of <i>Candida lusitanae</i> and <i>Candida guilliermondii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4953-4956.	3.2	16
154	Fungal DNA Detected in Blood Samples of Patients Who Received Contaminated Methylprednisolone Injections Reveals Increased Complexity of Causative Agents. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2212-2215.	3.9	10
155	Drug-resistant tuberculosis in two children in Greece: Report of the first extensively drug-resistant case. <i>European Journal of Pediatrics</i> , 2013, 172, 563-567.	2.7	7
156	Antifungal Prophylaxis in the Pediatric Intensive Care Unit. <i>Current Fungal Infection Reports</i> , 2013, 7, 361-371.	2.6	1
157	Increased virulence of <i>Cunninghamella bertholletiae</i> in experimental pulmonary mucormycosis: correlation with circulating molecular biomarkers, sporangiospore germination and hyphal metabolism. <i>Medical Mycology</i> , 2013, 51, 72-82.	0.7	44
158	Minireview: host defence in invasive aspergillosis. <i>Mycoses</i> , 2013, 56, 403-413.	4.0	66
159	<i>Aspergillus</i> fungal infections in chronic granulomatous disease. <i>Mycoses</i> , 2013, 56, 449-462.	4.0	40
160	Species-Specific and Drug-Specific Differences in Susceptibility of <i>Candida</i> Biofilms to Echinocandins: Characterization of Less Common Bloodstream Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2562-2570.	3.2	60
161	What Can We Learn and What Do We Need to Know Amidst the Iatrogenic Outbreak of <i>Exserohilum Rostratum</i> Meningitis?. <i>Clinical Infectious Diseases</i> , 2013, 57, 853-859.	5.8	24
162	Infections Caused by Carbapenem-resistant Gram-negative Pathogens in Hospitalized Children. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, e151-e154.	2.0	41

#	ARTICLE	IF	CITATIONS
163	Posaconazole: when and how? The clinician's view. <i>Mycoses</i> , 2012, 55, 110-122.	4.0	27
164	How Does Antifungal Pharmacology Differ for Mucormycosis Versus Aspergillosis?. <i>Clinical Infectious Diseases</i> , 2012, 54, S67-S72.	5.8	51
165	Daptomycin Use in a Neonate: Serum Level Monitoring and Outcome. <i>American Journal of Perinatology</i> , 2012, 29, 843-844.	1.4	0
166	Host Defenses Against Zygomycetes. <i>Clinical Infectious Diseases</i> , 2012, 54, S61-S66.	5.8	58
167	Invasive Aspergillosis in Children With Acquired Immunodeficiencies. <i>Clinical Infectious Diseases</i> , 2012, 54, 258-267.	5.8	40
168	Candida Osteomyelitis: Analysis of 207 Pediatric and Adult Cases (1970-2011). <i>Clinical Infectious Diseases</i> , 2012, 55, 1338-1351.	5.8	138
169	Immunotherapy against invasive mold infections. <i>Immunotherapy</i> , 2012, 4, 107-120.	2.0	12
170	Combination Therapy for Mucormycosis: Why, What, and How?. <i>Clinical Infectious Diseases</i> , 2012, 54, S73-S78.	5.8	139
171	Results From a Prospective, International, Epidemiologic Study of Invasive Candidiasis in Children and Neonates. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 1252-1257.	2.0	148
172	Serum levels of daptomycin in pediatric patients. <i>Infection</i> , 2012, 40, 367-371.	4.7	35
173	Epidemiology and Clinical Manifestations of Mucormycosis. <i>Clinical Infectious Diseases</i> , 2012, 54, S23-S34.	5.8	1,061
174	Application of diagnostic markers to invasive aspergillosis in children. <i>Annals of the New York Academy of Sciences</i> , 2012, 1272, 1-8.	3.8	19
175	Rhino-Orbital-Cerebral Mucormycosis. <i>Current Infectious Disease Reports</i> , 2012, 14, 423-434.	3.0	128
176	Is There Still a Place for Conventional Amphotericin B in the Treatment of Neonatal Fungal Infections?. <i>Current Fungal Infection Reports</i> , 2012, 6, 81-94.	2.6	0
177	Effects of interferon- γ and granulocyte colony-stimulating factor on antifungal activity of human polymorphonuclear neutrophils against <i>Candida albicans</i> grown as biofilms or planktonic cells. <i>Cytokine</i> , 2011, 55, 330-334.	3.2	34
178	Mucormycosis. , 2011, , 597-602.		1
179	Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy " is there a "right" choice?. <i>Current Opinion in Infectious Diseases</i> , 2011, 24, 163-171.	3.1	32
180	Antifungal activity of posaconazole and granulocyte colony-stimulating factor in the treatment of disseminated zygomycosis (mucormycosis) in a neutropaenic murine model. <i>Mycoses</i> , 2011, 54, e486-92.	4.0	16

#	ARTICLE	IF	CITATIONS
181	Osteomyelitis due to <i>Aspergillus</i> species in chronic granulomatous disease: an update of the literature. <i>Mycoses</i> , 2011, 54, e686-e696.	4.0	37
182	Invasive candidiasis in neonates and children. <i>Early Human Development</i> , 2011, 87, S75-S76.	1.8	38
183	Candidemia in the Pediatric Intensive Care Unit: What's Different from Candidemia in Adults?. <i>Current Fungal Infection Reports</i> , 2011, 5, 49-55.	2.6	0
184	Immunogenetic Variability Associated with Different Susceptibility Patterns to <i>Candida</i> and <i>Aspergillus</i> Infections. <i>Current Fungal Infection Reports</i> , 2011, 5, 141-150.	2.6	0
185	Risk of azole-enhanced vincristine neurotoxicity in pediatric patients with hematological malignancies: Old problem – New Dilemma. <i>Pediatric Blood and Cancer</i> , 2011, 57, 30-35.	1.5	27
186	Synergistic Interaction of the Triple Combination of Amphotericin B, Ciprofloxacin, and Polymorphonuclear Neutrophils against <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5923-5929.	3.2	8
187	Activities of Triazole-Echinocandin Combinations against <i>Candida</i> Species in Biofilms and as Planktonic Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1968-1974.	3.2	46
188	Immunomodulatory Properties of Antifungal Agents on Phagocytic Cells. <i>Immunological Investigations</i> , 2011, 40, 809-824.	2.0	13
189	Additive antifungal activity of anidulafungin and human neutrophils against <i>Candida parapsilosis</i> biofilms. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 588-591.	3.0	29
190	Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome (APECED) due to AIRE16M mutation in a consanguineous Greek girl. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2011, 24, 599-601.	0.9	6
191	Life-threatening infection due to community-acquired methicillin-resistant <i>Staphylococcus aureus</i> : case report and review. <i>European Journal of Pediatrics</i> , 2010, 169, 47-53.	2.7	16
192	Colistin administration to pediatric and neonatal patients. <i>European Journal of Pediatrics</i> , 2010, 169, 867-874.	2.7	70
193	Interactions between Human Phagocytes and <i>Candida albicans</i> Biofilms Alone and in Combination with Antifungal Agents. <i>Journal of Infectious Diseases</i> , 2010, 201, 1941-1949.	4.0	96
194	Serum and Cerebrospinal Fluid Levels of Colistin in Pediatric Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3985-3987.	3.2	61
195	<i>Cunninghamella bertholletiae</i> exhibits increased resistance to human neutrophils with or without antifungal agents as compared to <i>Rhizopus</i> spp.. <i>Medical Mycology</i> , 2010, 48, 720-724.	0.7	17
196	Local innate host response and filamentous fungi in patients with cystic fibrosis. <i>Medical Mycology</i> , 2010, 48, S22-S31.	0.7	15
197	Bloodstream Infections Caused by Metallo-β-Lactamase-Producing <i>Klebsiella pneumoniae</i> among Intensive Care Unit Patients in Greece: Risk Factors for Infection and Impact of Type of Resistance on Outcomes. <i>Infection Control and Hospital Epidemiology</i> , 2010, 31, 1250-1256.	1.8	160
198	Use of linezolid in pediatrics: a critical review. <i>International Journal of Infectious Diseases</i> , 2010, 14, e638-e648.	3.3	38

#	ARTICLE	IF	CITATIONS
199	Fungal infections in pediatric patients. , 2009, , 481-499.		3
200	Host immune response against <i>Scedosporium</i> species. Medical Mycology, 2009, 47, 433-440.	0.7	23
201	Invasive Aspergillosis in Paediatric Patients. , 2009, , 460-483.		0
202	Zygomycosis in Neonates: An Uncommon but Life-threatening Infection. American Journal of Perinatology, 2009, 26, 565-573.	1.4	54
203	A case of Listeria meningoenkephalitis complicated by hydrocephalus in an immunocompetent infant. European Journal of Pediatrics, 2009, 168, 343-346.	2.7	6
204	Augmentation of innate host defenses against opportunistic fungal pathogens. Current Fungal Infection Reports, 2009, 3, 186-191.	2.6	1
205	Aspergillus and the paediatric lung. Paediatric Respiratory Reviews, 2009, 10, 178-185.	1.8	20
206	Invasive Fungal Infections in Children. Pediatric Infectious Disease Journal, 2009, 28, 734-737.	2.0	49
207	Osteoarticular and Epidural Infections. , 2009, , 853-862.		0
208	The role of immunostimulation in the treatment of invasive fungal infection. Current Fungal Infection Reports, 2008, 2, 28-35.	2.6	1
209	Cutaneous zygomycosis in an infant with Pearson syndrome. Pediatric Blood and Cancer, 2008, 50, 939-940.	1.5	9
210	Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes. Mycoses, 2008, 51, 147-154.	4.0	30
211	Antifungal Activity of Posaconazole and Granulocyte Colony-Stimulating Factor in the Treatment of Disseminated Zygomycosis in a Neutropenic Murine Model. International Journal of Infectious Diseases, 2008, 12, S48.	3.3	1
212	Differential Correlation Between Rates of Antimicrobial Drug Consumption and Prevalence of Antimicrobial Resistance in a Tertiary Care Hospital in Greece. Infection Control and Hospital Epidemiology, 2008, 29, 615-622.	1.8	52
213	Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients. Expert Opinion on Pharmacotherapy, 2008, 9, 3179-3196.	1.8	8
214	Infections Caused by <i>Scedosporium</i> spp. Clinical Microbiology Reviews, 2008, 21, 157-197.	13.6	640
215	Amphotericin B formulations variably enhance antifungal activity of human neutrophils and monocytes against <i>Fusarium solani</i> : comparison with <i>Aspergillus fumigatus</i> . Journal of Antimicrobial Chemotherapy, 2008, 61, 810-817.	3.0	25
216	Differential Activities of Newer Antifungal Agents against <i>Candida albicans</i> and <i>Candida parapsilosis</i> Biofilms. Antimicrobial Agents and Chemotherapy, 2008, 52, 357-360.	3.2	114

#	ARTICLE	IF	CITATIONS
217	Host-Dependent Patterns of Tissue Injury in Invasive Pulmonary Aspergillosis. <i>American Journal of Clinical Pathology</i> , 2007, 127, 349-355.	0.7	137
218	Immunomodulatory therapy in yeast infections. <i>Expert Review of Anti-Infective Therapy</i> , 2007, 5, 129-140.	4.4	3
219	Fungal Colonization in the Neonatal Intensive Care Unit: Risk Factors, Drug Susceptibility, and Association with Invasive Fungal Infections. <i>American Journal of Perinatology</i> , 2007, 24, 127-135.	1.4	45
220	Zygomycosis in Children: A Systematic Review and Analysis of Reported Cases. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 723-727.	2.0	219
221	Central nervous system aspergillosis in children: a systematic review of reported cases. <i>International Journal of Infectious Diseases</i> , 2007, 11, 381-393.	3.3	85
222	Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome. <i>Intensive Care Medicine</i> , 2007, 33, 1272-1283.	8.2	102
223	Fungal infections in primary immunodeficiencies. <i>European Journal of Pediatrics</i> , 2007, 166, 1099-1117.	2.7	154
224	Generation of highly purified and functionally active human TH1 cells against <i>Aspergillus fumigatus</i> . <i>Blood</i> , 2006, 107, 2562-2569.	1.4	115
225	Deoxycholate amphotericin B and amphotericin B lipid complex exert additive antifungal activity in combination with pulmonary alveolar macrophages against <i>Fusarium solani</i> . <i>Mycoses</i> , 2006, 49, 109-113.	4.0	6
226	Interleukin-4 suppresses antifungal activity of human mononuclear phagocytes against <i>Candida albicans</i> in association with decreased uptake of blastoconidia. <i>FEMS Immunology and Medical Microbiology</i> , 2006, 19, 169-180.	2.7	27
227	Acquisition of imipenem-resistant <i>Acinetobacter baumannii</i> in a pediatric intensive care unit: a case-control study. <i>Intensive Care Medicine</i> , 2006, 32, 1384-1391.	8.2	47
228	Early diagnosis of invasive aspergillosis in infants and children. <i>Medical Mycology</i> , 2006, 44, 199-205.	0.7	25
229	Rapid Susceptibility Testing of Medically Important Zygomycetes by XTT Assay. <i>Journal of Clinical Microbiology</i> , 2006, 44, 553-560.	3.9	49
230	Fungemia due to <i>Trichosporon asahii</i> in a Neutropenic Child Refractory to Amphotericin B. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 283-285.	0.6	50
231	Cytokines and fungal infections. <i>British Journal of Haematology</i> , 2005, 129, 583-596.	2.5	109
232	Transforming growth factor- β 1 in the urine of young children with urinary tract infection. <i>Pediatric Nephrology</i> , 2005, 20, 180-183.	1.7	11
233	Expression of Genes Encoding Innate Host Defense Molecules in Normal Human Monocytes in Response to <i>Candida albicans</i> . <i>Infection and Immunity</i> , 2005, 73, 3714-3724.	2.2	82
234	Interferon- γ and Granulocyte-Macrophage Colony-Stimulating Factor Augment the Activity of Polymorphonuclear Leukocytes against Medically Important Zygomycetes. <i>Journal of Infectious Diseases</i> , 2005, 191, 1180-1187.	4.0	157

#	ARTICLE	IF	CITATIONS
235	Successful Treatment of Multidrug-Resistant <i>Acinetobacter baumannii</i> Central Nervous System Infections with Colistin. <i>Journal of Clinical Microbiology</i> , 2005, 43, 4916-4917.	3.9	63
236	Interferon gamma and granulocyte macrophage colony-stimulating factor augment the antifungal activity of human polymorphonuclear leukocytes against <i>Scedosporium</i> spp.: comparison with <i>Aspergillus</i> spp.. <i>Medical Mycology</i> , 2005, 43, 253-260.	0.7	59
237	Effects of interleukin-15 on antifungal responses of human polymorphonuclear leukocytes against <i>Fusarium</i> spp. and <i>Scedosporium</i> spp.. <i>Cytokine</i> , 2005, 31, 1-8.	3.2	29
238	Functional Characterization of <i>Aspergillus fumigatus</i> Specific T-Cells Clones.. <i>Blood</i> , 2005, 106, 3223-3223.	1.4	1
239	Osteomyelitis due to <i>Aspergillus</i> spp. in patients with chronic granulomatous disease: comparison of <i>Aspergillus nidulans</i> and <i>Aspergillus fumigatus</i> . <i>International Journal of Infectious Diseases</i> , 2004, 8, 103-110.	3.3	78
240	Recombinant cytokines in augmentation and immunomodulation of host defenses against <i>Candida</i> spp.. <i>Medical Mycology</i> , 2004, 42, 1-13.	0.7	24
241	Immune haemolytic anaemia due to visceral leishmaniasis in a young child. <i>European Journal of Pediatrics</i> , 2003, 162, 49-50.	2.7	5
242	Cerebral aspergillosis in an infant with corticosteroid-resistant nephrotic syndrome. <i>Pediatric Nephrology</i> , 2003, 18, 450-453.	1.7	26
243	Immune haemolytic anaemia due to visceral leishmaniasis in a young child. <i>European Journal of Pediatrics</i> , 2003, 162, 445-445.	2.7	0
244	Macrophage colony-stimulating factor enhances phagocytosis and oxidative burst of mononuclear phagocytes against <i>Penicillium marneffe</i> conidia. <i>FEMS Immunology and Medical Microbiology</i> , 2003, 36, 19-26.	2.7	21
245	Immunomodulation of invasive fungal infections. <i>Infectious Disease Clinics of North America</i> , 2003, 17, 193-219.	5.1	27
246	Human Phagocytic Cell Responses to <i>Scedosporium apiospermum</i> (<i>Pseudallescheria boydii</i>): Variable Susceptibility to Oxidative Injury. <i>Infection and Immunity</i> , 2003, 71, 6472-6478.	2.2	29
247	<i>Candida tropicalis</i> in a Neonatal Intensive Care Unit: Epidemiologic and Molecular Analysis of an Outbreak of Infection with an Uncommon Neonatal Pathogen. <i>Journal of Clinical Microbiology</i> , 2003, 41, 735-741.	3.9	76
248	Interactions of human phagocytes with moulds <i>Fusarium</i> spp. and <i>Verticillium nigrescens</i> possessing different pathogenicity. <i>Medical Mycology</i> , 2003, 41, 503-509.	0.7	12
249	Antifungal Triazoles and Polymorphonuclear Leukocytes Synergize To Cause Increased Hyphal Damage to <i>Scedosporium prolificans</i> and <i>Scedosporium apiospermum</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 2234-2237.	3.2	57
250	Amphotericin B lipid complex exerts additive antifungal activity in combination with polymorphonuclear leukocytes against <i>Scedosporium prolificans</i> and <i>Scedosporium apiospermum</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 50, 1027-1030.	3.0	49
251	Amphotericin B Formulations Exert Additive Antifungal Activity in Combination with Pulmonary Alveolar Macrophages and Polymorphonuclear Leukocytes against <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 1974-1976.	3.2	49
252	Cytokines in immunodeficient patients with invasive fungal infections: an emerging therapy. <i>International Journal of Infectious Diseases</i> , 2002, 6, 154-163.	3.3	38

#	ARTICLE	IF	CITATIONS
253	TRICHOSPORON ASAHII: AN UNUSUAL CAUSE OF INVASIVE INFECTION IN NEONATES. <i>Pediatric Infectious Disease Journal</i> , 2002, 21, 169-170.	2.0	27
254	RECOMBINANT HUMAN MACROPHAGE COLONY-STIMULATING FACTOR AUGMENTS PULMONARY HOST DEFENCES AGAINST ASPERGILLUS FUMIGATUS. <i>Cytokine</i> , 2001, 15, 87-95.	3.2	34
255	Immunotherapy in Patients with Systemic Mycoses. <i>BioDrugs</i> , 2001, 15, 207-214.	4.6	11
256	Effects of Macrophage Colony-Stimulating Factor on Antifungal Activity of Neonatal Monocytes against <i>Candida albicans</i> . <i>Neonatology</i> , 2001, 80, 251-256.	2.0	5
257	Elevated Serum Concentrations of Interleukin-10 in Nonneutropenic Patients with Invasive Aspergillosis. <i>Journal of Infectious Diseases</i> , 2001, 183, 518-520.	4.0	69
258	INTERLEUKIN 10 SUPPRESSES PHAGOCYtic AND ANTIHYPHAL ACTIVITIES OF HUMAN NEUTROPHILS. <i>Cytokine</i> , 2000, 12, 379-387.	3.2	37
259	Increased Urine Interleukin-6 Concentrations Correlate with Pyelonephritic Changes on ^{99mTc} -Dimercaptosuccinic Acid Scans in Neonates with Urinary Tract Infections. <i>Journal of Infectious Diseases</i> , 1999, 180, 904-907.	4.0	47
260	Disseminated Infection Due to <i>Chrysosporium zonatum</i> in a Patient with Chronic Granulomatous Disease and Review of Non- <i>Aspergillus</i> Fungal Infections in Patients with This Disease. <i>Journal of Clinical Microbiology</i> , 1999, 37, 18-25.	3.9	84
261	Tumor Necrosis Factor Alpha Enhances Antifungal Activities of Polymorphonuclear and Mononuclear Phagocytes against <i>Aspergillus fumigatus</i> . <i>Infection and Immunity</i> , 1998, 66, 5999-6003.	2.2	133
262	Invasive candidosis in pediatric patients. <i>Clinical Microbiology and Infection</i> , 1997, 3, 192-197.	6.0	31
263	Interleukin-4 suppresses antifungal activity of human mononuclear phagocytes against <i>Candida albicans</i> in association with decreased uptake of blastoconidia. <i>FEMS Immunology and Medical Microbiology</i> , 1997, 19, 169-180.	2.7	1
264	Ex vivo effects of macrophage colony-stimulating factor on human monocyte activity against fungal and bacterial pathogens. <i>Cytokine</i> , 1996, 8, 42-48.	3.2	41
265	Effects of granulocyte colony-stimulating factor and interferon- γ on antifungal activity of human polymorphonuclear neutrophils against pseudohyphae of different medically important <i>Candida</i> species. <i>Journal of Leukocyte Biology</i> , 1995, 57, 651-656.	3.3	86
266	Perspectives on the Use of Cytokines in the Management of Infectious Complications of Cancer. <i>Clinical Infectious Diseases</i> , 1993, 17, S385-S389.	5.8	17
267	Modulation of Host Defenses by Cytokines: Evolving Adjuncts in Prevention and Treatment of Serious Infections in Immunocompromised Hosts. <i>Clinical Infectious Diseases</i> , 1992, 15, 508-524.	5.8	95
268	Recent progress and current problems in management of invasive fungal infections in patients with neoplastic diseases. <i>Current Opinion in Oncology</i> , 1992, 4, 647-656.	2.4	23
269	Helper T-cell responses in children infected with human immunodeficiency virus type 1. <i>Journal of Pediatrics</i> , 1991, 118, 724-730.	1.8	72
270	Evaluation of Molecular Responses and Antifungal Activity of Phagocytes to Opportunistic Fungi. , 0, , 43-68.		1

#	ARTICLE	IF	CITATIONS
271	How Biofilms Evade Host Defenses. , 0, , 287-300.		8
272	Antifungal drug dosing adjustment in critical patients with invasive fungal infections. Journal of Emergency and Critical Care Medicine, 0, 3, 37-37.	0.7	7
273	Aspergillosis in Pediatric Patients. , 0, , 531-546.		0
274	Molecular Immunopathogenesis of Innate Host Defense against Chronic Disseminated (Hepatosplenic) Candidiasis. , 0, , 583-588.		0